CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin’s Lymphoma

Documenti analoghi

• Targeting CD138−/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity
  di: Lum, Lawrence G., et al.
  Pubblicazione: (2016)
• Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease
  di: Bhutani, Divaya, et al.
  Pubblicazione: (2014)
• High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplantation Patients
  di: Al-Kadhimi, Zaid, et al.
  Pubblicazione: (2014)
• Vaccination with bispecific antibody armed T cells (BATC) in metastatic breast cancer patients and transfer of anti-breast cancer immunity in primed T cells after stem cell transplant: a proof of principle study
  di: Thakur, Archana, et al.
  Pubblicazione: (2015)
• Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial
  di: Abidi, Muneer H., et al.
  Pubblicazione: (2012)